Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Febuxostat tablets, which are intended for the long-term treatment of hyperuricemia and gout patients, marking a significant step in expanding its product line [1] Group 1: Product Registration - The registration of Febuxostat tablets is classified as a Class 4 chemical drug, equivalent to passing the consistency evaluation of generic drug quality and efficacy [1] - This approval allows the company to sell the drug in the domestic market, enhancing its product offerings [1] Group 2: Market Considerations - Future sales of the product may be influenced by national policies, market demand, and competition from similar drugs, indicating potential uncertainties in its market performance [1]

湖北亨迪药业股份有限公司于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 | 药品名称 | 非布司他片 | | --- | --- | | 剂型 | 片剂 | | 规格 | 20mg；40mg | | 注册分类 | 化学药品 4 类 | | 药品有效期 | 18 个月 | | 上市许可持有人 | 湖北亨迪药业股份有限公司 | | 生产企业 | 湖北亨迪药业股份有限公司 | | 受理号 | CYHS2401513；CYHS2401512 | | 证书编号 | 2025S03126、2025S03125 | | 药品批准文号 | 国药准字 H20255686；国药准字 H20255685 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审 | | | 查，本品符合药品注册的有关要求，批准注册，发给药品注 | | | 册证书。质量标准、说明书、标签及生产工艺照所附执行。 | | | 药品生产企业应当符合药品生产质量管理规范要求方可生 | | | 产销售。 | 二、药品的其他相关情况 非布司他片是一种黄嘌呤氧化酶抑制剂，主 ...

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Core Viewpoint - The flu-related stocks experienced a significant surge on October 21, with notable increases in companies such as Te Yi Pharmaceutical, Jinshi Yao, and Hualan Vaccine, driven by rising flu activity in southern China and predictions of an earlier flu season this year [1][4]. Group 1: Stock Performance - Te Yi Pharmaceutical reached a trading limit with a price of 10.27, reflecting a 9.96% increase [2] - Jinshi Yao saw a price increase to 11.73, marking a 15.11% rise [2] - Hualan Vaccine's stock rose to 22.15, showing an 11.87% increase [2] - New Ganjing's stock price increased to 23.72, with a rise of 11.41% [2] - Other companies like Hengdi Pharmaceutical and Xiangrikui also followed the upward trend [1]. Group 2: Flu Activity and Predictions - The China CDC reported an increase in flu activity in southern provinces, indicating a potential early onset of the flu season this year [4] - Experts noted that the predominant flu strain this year is H3N2, differing from last year's H1N1 strain, which may lead to lower immunity levels in the population [5]. Group 3: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for individuals to get vaccinated between September and November [8] - The flu vaccine needs to be administered annually due to the rapid mutation of the virus, ensuring protection against the current year's strains [8][9]. - High-risk groups, including children under 5, the elderly, and individuals with chronic health conditions, are advised to prioritize vaccination [12].

Group 1 - The core viewpoint of the article highlights a significant rise in flu-related stocks, with companies like Te Yi Pharmaceutical hitting the daily limit, and others like Jinshi Yao, Hualan Vaccine, and Xin Ganjing seeing increases of over 10% [1][2] - The flu activity in southern China is on the rise, with experts predicting an earlier flu season this year compared to last, and the circulating strain being different from the previous year [2][3] - The predominant strain this year is H3N2, which may lead to lower immunity in the population compared to last year's H1N1 strain, necessitating increased attention [4][5] Group 2 - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for vaccination between September and November to ensure effective immunity before peak season [6][7] - The article discusses the differences between trivalent and quadrivalent flu vaccines, noting that while quadrivalent vaccines cover an additional strain, the practical difference in effectiveness is minimal [10] - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to prioritize flu vaccination [12]

Core Viewpoint - The article highlights the rising flu activity in southern China, with predictions of an earlier flu season this year compared to last, primarily driven by the different circulating strain, H3N2, which the public has lower immunity against [2][3]. Group 1: Flu Activity and Strain Information - The current flu season is characterized by the predominance of the H3N2 strain, contrasting with last year's H1N1 strain, indicating a need for heightened awareness due to lower public immunity [3]. - Clinical symptoms of H3N2 include high fever, cough, sore throat, body aches, fatigue, and headache, which are similar to other flu strains [3]. Group 2: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with the recommended vaccination period being from September to November to ensure immunity before peak season [5]. - Annual vaccination is necessary due to the rapid mutation of flu viruses, which may differ from year to year, thus requiring updated protection [6]. - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to receive vaccinations promptly [10]. Group 3: Vaccine Types and Administration - The available flu vaccines in China include inactivated (split) vaccines (trivalent/quadrivalent), inactivated (subunit) vaccines (trivalent/quadrivalent), and live attenuated vaccines (trivalent, nasal spray) [8]. - The difference between trivalent and quadrivalent vaccines lies in the number of virus strains they protect against, with quadrivalent covering an additional B strain, although the practical effectiveness may not differ significantly [8].

证券日报网讯 10月15日晚间，亨迪药业（301211）发布公告称，公司于2025年10月15日召开2025年第 二次职工代表大会，经与会职工代表审议，同意选举陈吉人先生为公司第二届董事会职工代表董事。 ...

南财智讯10月15日电，亨迪药业公告，公司董事肖云华先生因个人原因辞去董事及董事会战略委员会委 员职务，辞职后不再担任公司任何职务。公司于2025年10月15日召开职工代表大会，选举陈吉人先生为 新的职工代表董事，任期至第二届董事会届满。 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-044 湖北亨迪药业股份有限公司 关于董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 三、备查文件 1、公司 2025 年第二次职工代表大会会议决议。 特此公告。 湖北亨迪药业股份有限公司 2025 年 10 月 15 日 湖北亨迪药业股份有限公司董事会于近日收到公司董事肖云华先生的书面 辞职报告。肖云华先生因个人原因，申请辞去公司董事职务，同时一并辞去公司 董事会战略委员会职务，辞去上述职务后肖云华先生将不在公司担任任何职务。 公司对肖云华先生任职期间的勤勉尽责以及对公司做出的贡献表示衷心的感谢。 肖云华先生作为第二届董事会董事的原定任期为2023年6月21日起至2026 年 6 月 21 日。根据《公司法》及《公司章程》等有关规定，肖云华先生辞任董 事不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运 作，其辞职报告自送达公司董事会之日起生效。 截至本公告披露日，肖云华先生未持有公司股份，不存在应当履行而未履行 的承诺事项。辞去董事职务后将继 ...

证券日报网讯 10月13日晚间，亨迪药业发布公告称，公司于2025年9月2日召开第二届董事会第十五次 会议、2025年9月18日召开了2025年第二次临时股东大会，审议通过了《关于变更公司注册资本、修订 公司章程并办理工商变更登记的议案》，同意公司变更注册资本及修订《公司章程》并由董事会指定相 关人员办理工商登记。 （文章来源：证券日报） ...